Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)

NCT06926790 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer - Non Small Cell

Interventions

DRUG: Nivolumab & Ipilimumab

Sponsor

The First Affiliated Hospital of Guangzhou Medical University